Literature DB >> 27141365

Myeloid cells in the tumor microenvironment: Role of adenosine.

Silvana Morello1, Aldo Pinto1, Corrado Blandizzi2, Luca Antonioli2.   

Abstract

Adenosine, deriving from ATP released by dying cancer cells and then degradated in the tumor environment by CD39/CD73 enzyme axis, is linked to the generation of an immunosuppressed niche favoring the onset of neoplasia. The effects of adenosine are mediated by four adenosine receptors, named A1, A2A, A2B and A3 that are widely expressed on several immune cell populations. A critical role of this nucleoside is emerging in the modulation of myeloid cell subsets accumulation and functions into tumor microenvironment, providing new insights that might be useful for the development of novel therapeutic approaches aimed to undermine the immune privileged sites where cancer cells grow and proliferate.

Entities:  

Keywords:  Adenosine receptors; adenosine; cancer; immune system; myeloid cells; tumor microenvironment

Year:  2015        PMID: 27141365      PMCID: PMC4839347          DOI: 10.1080/2162402X.2015.1108515

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  88 in total

Review 1.  Myeloid-derived suppressor cells in cancer patients: a clinical perspective.

Authors:  Alberto J Montero; Claudia Marcela Diaz-Montero; Christos E Kyriakopoulos; Vincenzo Bronte; Susanna Mandruzzato
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

2.  Ecto-5'-nucleotidase (CD73) decreases mortality and organ injury in sepsis.

Authors:  György Haskó; Balázs Csóka; Balázs Koscsó; Rachna Chandra; Pál Pacher; Linda F Thompson; Edwin A Deitch; Zoltán Spolarics; László Virág; Pál Gergely; Rolando H Rolandelli; Zoltán H Németh
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

Review 3.  The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Authors:  Gregory K Pennock; Laura Q M Chow
Journal:  Oncologist       Date:  2015-06-11

4.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

5.  Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells.

Authors:  C A Salvatore; S L Tilley; A M Latour; D S Fletcher; B H Koller; M A Jacobson
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

6.  Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.

Authors:  Caglar Cekic; Yuan-Ji Day; Duygu Sag; Joel Linden
Journal:  Cancer Res       Date:  2014-11-06       Impact factor: 12.701

7.  Identification of A3 receptor- and mast cell-dependent and -independent components of adenosine-mediated airway responsiveness in mice.

Authors:  Stephen L Tilley; Mindy Tsai; Cara M Williams; Z-S Wang; Christopher J Erikson; Stephen J Galli; Beverly H Koller
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

8.  The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells.

Authors:  Jeffrey M Wilson; William G Ross; Oma N Agbai; Renea Frazier; Robert A Figler; Jayson Rieger; Joel Linden; Peter B Ernst
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

9.  IL-4 amplifies the pro-inflammatory effect of adenosine in human mast cells by changing expression levels of adenosine receptors.

Authors:  Xiaoyang Hua; Kelly D Chason; Janki Y Patel; Warren C Naselsky; Stephen L Tilley
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

Review 10.  Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer.

Authors:  Hiroshi Katoh; Masahiko Watanabe
Journal:  Mediators Inflamm       Date:  2015-05-19       Impact factor: 4.711

View more
  22 in total

1.  Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma.

Authors:  Xiaolin Liu; Weiwei Nie; Qi Xie; Guoling Chen; Xingyu Li; Yanrui Jia; Beibei Yin; Xun Qu; Yan Li; Jing Liang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

Review 2.  Trial watch: Dendritic cell-based anticancer immunotherapy.

Authors:  Abhishek D Garg; Monica Vara Perez; Marco Schaaf; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-05-12       Impact factor: 8.110

Review 3.  Myeloid cell-targeted therapies for solid tumours.

Authors:  Sangeeta Goswami; Swetha Anandhan; Deblina Raychaudhuri; Padmanee Sharma
Journal:  Nat Rev Immunol       Date:  2022-06-13       Impact factor: 53.106

Review 4.  Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.

Authors:  Qing Li; Ming Xiang
Journal:  Acta Pharmacol Sin       Date:  2021-09-24       Impact factor: 7.169

Review 5.  Tumor-related stress regulates functional plasticity of MDSCs.

Authors:  Jessica K Mandula; Paulo C Rodriguez
Journal:  Cell Immunol       Date:  2021-02-12       Impact factor: 4.868

6.  Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors.

Authors:  Sonja Hinz; Gemma Navarro; Dasiel Borroto-Escuela; Benjamin F Seibt; York-Christoph Ammon; Elisabetta de Filippo; Azeem Danish; Svenja K Lacher; Barbora Červinková; Muhammad Rafehi; Kjell Fuxe; Anke C Schiedel; Rafael Franco; Christa E Müller
Journal:  Oncotarget       Date:  2018-02-06

7.  Fasting inhibits colorectal cancer growth by reducing M2 polarization of tumor-associated macrophages.

Authors:  Pengfei Sun; Huihui Wang; Zhiyong He; Xiangyuan Chen; Qichao Wu; Wankun Chen; Zhirong Sun; Meilin Weng; Minmin Zhu; Duan Ma; Changhong Miao
Journal:  Oncotarget       Date:  2017-08-16

8.  Adenosine A2A Receptor Stimulation Inhibits TCR-Induced Notch1 Activation in CD8+T-Cells.

Authors:  Claudia Sorrentino; Fokhrul Hossain; Paulo C Rodriguez; Rosa A Sierra; Antonio Pannuti; Barbara A Osborne; Lisa M Minter; Lucio Miele; Silvana Morello
Journal:  Front Immunol       Date:  2019-02-07       Impact factor: 7.561

Review 9.  Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.

Authors:  Chunmei Fan; Shanshan Zhang; Zhaojian Gong; Xiayu Li; Bo Xiang; Hao Deng; Ming Zhou; Guiyuan Li; Yong Li; Wei Xiong; Zhaoyang Zeng; Xiaoling Li
Journal:  Sci China Life Sci       Date:  2020-08-17       Impact factor: 6.038

Review 10.  Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.

Authors:  Mithunah Krishnamoorthy; Lara Gerhardt; Saman Maleki Vareki
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.